URGN CLASS ACTION: Invest in UroGen Pharma Ltd.? Contact BFA Law about the Pending Securities Fraud Class Action to Potentially Recover Losses (NASDAQ:URGN)

Core Viewpoint - A lawsuit has been filed against UroGen Pharma Ltd. and certain senior executives for potential violations of federal securities laws, specifically related to the company's claims about its lead product UGN-102 and its clinical trial results [1][2]. Company Overview - UroGen Pharma Ltd. focuses on developing treatments for specialty cancers, with its lead product being UGN-102, an intravesical solution aimed at treating low-grade intermediate risk non-muscle invasive bladder cancer [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Cockrell v. UroGen Pharma Ltd., et al., No. 3:25-cv-06088, and investors have until July 28, 2025, to seek lead plaintiff status [2]. Allegations - The complaint alleges that UroGen misrepresented the success of the ENVISION trial, claiming it met its primary endpoint and that the FDA had agreed the trial would support a New Drug Application (NDA) submission [3]. - In reality, the FDA had raised significant concerns about the trial's design, particularly its lack of a concurrent control arm [4]. Stock Performance - Following the FDA's briefing document on May 16, 2025, which questioned the effectiveness of UGN-102, UroGen's stock price fell by $2.54 per share, a decline of nearly 26%, from $9.85 to $7.31 [5]. - On May 21, 2025, after the Oncologic Drugs Advisory Committee voted against the approval of the UGN-102 NDA, the stock dropped by $3.37 per share, nearly 45%, from $7.54 to $4.17 [6]. Legal Options for Investors - Investors who suffered losses are encouraged to submit their information to the law firm representing the class action, with representation on a contingency fee basis [7].